Plain-English translation of NCT05269485 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a combination approach for advanced lung cancer: first, concentrated radiation therapy (given over 2–3 weeks), followed by one year of immune checkpoint inhibitors to help your body's immune system fight cancer cells. The study will compare two different radiation dose levels to see which works best and causes the fewest side effects.
Standard treatments for advanced lung cancer that can't be surgically removed have limited success. Researchers believe that combining focused radiation with immune-boosting medication might work better together than either treatment alone, by using radiation to activate your immune system and the medication to keep it fighting.
You would receive radiation therapy over 2–3 weeks (either a higher dose or lower dose, assigned randomly), then begin one year of immune checkpoint inhibitor medication. Throughout the trial, you'll have regular check-in visits with imaging scans (CT, MRI, PET scans) and blood tests to monitor how well the treatment is working and watch for side effects. The study expects to enroll 36 patients total and is currently recruiting.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China